AMPHIREGULIN AND EPIREGULIN POLYMORPHISMS AS PHARMACOGENETIC PREDICTIVE FACTORS FOR RESPONSE TO IRINOTECAN PLUS ANTI-EGFR TREATMENT

被引：0
|
作者：
Sebio Garcia, A. [1 ]
Paez, D. [1 ]
Salazar Blanco, J. [1 ]
Tobena Puyal, M. [1 ]
Martin-Richard, M. [1 ]
Barnadas, A. [1 ]
Baiget, M. [1 ]
机构：
[1] Santa Creu & St Pau Hosp, Deparment Genet, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [41] Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
    Rosa Calemma
    Alessandro Ottaiano
    Anna Maria Trotta
    Guglielmo Nasti
    Carmela Romano
    Maria Napolitano
    Domenico Galati
    Pasquale Borrelli
    Serena Zanotta
    Antonino Cassata
    Giuseppe Castello
    Vincenzo Rosario Iaffaioli
    Stefania Scala
    Journal of Translational Medicine, 10
  • [42] EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?
    Cioce, Mario
    Fazio, Vito Michele
    CANCERS, 2021, 13 (04) : 1 - 23
  • [43] Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis
    Stock, Gustavo
    Aguiar, Pedro, Jr.
    Santoro, Ilka
    Tadokoro, Hakaru
    De Mello, Ramon
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S333 - S334
  • [44] Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias
    Statagno, Fabio
    Vigneri, Paoloaolo
    Del Fabro, Vittorio
    Stella, Stefania
    Restuccia, Nunzio
    Giallongo, Cesarina
    Massimino, Michele
    Berretta, Salvatore
    Pennisi, Maria Stella
    Tibullo, Daniele
    Tirro, Elena
    Buscarino, Calogero
    Messina, Angelo
    Di Raimondo, Francesco
    ACTA ONCOLOGICA, 2010, 49 (01) : 111 - 112
  • [45] Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
    Calemma, Rosa
    Ottaiano, Alessandro
    Trotta, Anna Maria
    Nasti, Guglielmo
    Romano, Carmela
    Napolitano, Maria
    Galati, Domenico
    Borrelli, Pasquale
    Zanotta, Serena
    Cassata, Antonino
    Castello, Giuseppe
    Iaffaioli, Vincenzo Rosario
    Scala, Stefania
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [46] Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment
    Arantes, Lidia Maria Rebolho Batista
    Silva-Oliveira, Renato Jose
    de Carvalho, Ana Carolina
    Melendez, Matias Eliseo
    Sorroche, Bruna Pereira
    Teixeira, Renan de Jesus
    Tostes, Katiane
    Palmero, Edenir Inez
    Reis, Rui Manuel
    Carvalho, Andre Lopes
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (03): : 461 - 472
  • [47] BASAL immunologic response and its modifications after treatment with ANTI-EGFR in patients with advanced colorectal cancer.
    Vieitez, Jose M.
    Moro-Garcia, Marco
    Jimenez-Fonseca, Paula
    de Echeverria, Carlos A.
    Iglesias Escudero, Mar
    Sanchez Lorenzo, Luisa
    Solis Hernandez, Maria Del Pilar
    Alonso, Rebeca
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [48] Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
    Llovet, Patricia
    Sastre, Javier
    Sanz Ortega, Julian
    Bando, Inmaculada
    Ferrer, Milagros
    Garcia-Alfonso, Pilar
    Donnay, Olga
    Carrato, Alfredo
    Jimenez, Ana
    Aranda, Enrique
    Leon, Ana
    Gravalos, Cristina
    Carlos Camara, Juan
    Feliu, Jaime
    Sanchiz, Barbara
    Caldes, Trinidad
    Diaz-Rubio, Eduardo
    MOLECULAR DIAGNOSIS & THERAPY, 2015, 19 (06) : 397 - 408
  • [49] Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer
    Fakih, Marwan G.
    FUTURE ONCOLOGY, 2011, 7 (02) : 223 - 226
  • [50] Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
    Patricia Llovet
    Javier Sastre
    Julián Sanz Ortega
    Inmaculada Bando
    Milagros Ferrer
    Pilar García-Alfonso
    Olga Donnay
    Alfredo Carrato
    Ana Jiménez
    Enrique Aranda
    Ana León
    Cristina Grávalos
    Juan Carlos Cámara
    Jaime Feliú
    Bárbara Sanchíz
    Trinidad Caldés
    Eduardo Díaz-Rubio
    Molecular Diagnosis & Therapy, 2015, 19 : 397 - 408
12345